
Dyve Biosciences is proud to announce FDA clearance to initiate phase 2 study of DYV-700 for treatment of acute #gout pain. Full press release: tinyurl.com/qk4vtzm

Dyve creates novel therapeutics using proprietary science that leverages the skin as a portal for systemic delivery.

Dyve Biosciences is proud to announce FDA clearance to initiate phase 2 study of DYV-700 for treatment of acute #gout pain. Full press release: tinyurl.com/qk4vtzm

Dyve’s science has demonstrated the power to deliver up to 40% of the applied dose into the blood, which exceeds what is seen by many pills. #biotech

Thank you to @MassDevice for highlighting Dyve's press release announcing first patient enrollment in Phase 2 TARGETS Study for Acute Gout: https://t.co/Z7Y4X5Uh1o #gout #biotech #clinicaltrials

Thank you @Machiz and @Nasdaq for featuring Dyve in their #NasdaqSpotlight series in New York City last week! You can view the full interview with CEO Ryan Beal on Dyve's website: https://t.co/2kjYnPvCDW #biotech #healthcare


We had an exciting week in New York! Thank you to @IAmBiotech for hosting #BIOCEO20 as well as @Nasdaq for highlighting Dyve on #NasdaqSpotlight! #biotech

Thanks to @byndergroup for their continued partnership and the amazing work they've put into developing our website! dyvebio.com
This tweet is unavailable

BIO is helping leaders fulfill that commitment by providing resources to help build a more inclusive and diverse workforce. Learn more at buff.ly/2S3JkIT #rightmixmatters

Dyve is thrilled to welcome longtime Pfizer Executive Chuck Harbert, Ph.D. to the company in the role of Chief Scientific Officer. Full press release: tinyurl.com/yexnmx99 Learn more about Dyve: dyvebio.com

Gout flares are characterized by the formation of sodium urate crystals in the joint space, causing intense pain typically lasting 48-96 hours.

.@DyveBio wins FDA nod for Phase 2 transdermal drug delivery trial https://t.co/nOaK6V0HF3

DYV-700 was recently approved for phase 2 trial for treatment of acute gout pain. Here's why we're excited.

CEO Ryan Beal, MD chatted with @ModAesthetics about the latest research on Dyve's technology. Check out the full article: https://t.co/ZnZ2l4gVMV

When should lasers be used to treat #melasma? Mildred López Piñeiro, M.D. provides her insight in our new column on energy devices. buff.ly/2QqsUeJ

Dyve's SAB member Smitha Reddy, MD with CEO Ryan Beal, MD before Dr. Reddy's poster presentation at #ACR19 in Atlanta. For the complete poster, visit our publications page on our website: dyvebio.com/newsroom/publica…
